(Invited) Brief Review: Progress of Tumor Active Targeting Bionic Nano-delivery System for Improving Tumor Immunotherapy Research

In recent years, immunotherapy has made significant progress in treating tumors. However, in the process of immunotherapeutic drug delivery in vivo, there are still problems, such as poor specificity, low penetration rate of deep tumor and low cellular uptake rate. These issues result in poor efficacy and safety. As a result, the therapeutic efficacy and safety of immunotherapy drugs are poor, which seriously limits the clinical effect of immunotherapy. Through the interaction between surface-coupled antibodies or ligands and target cell membrane receptors, the design and construction of Active Tumor targeting Biomimetic Nano Drug Delivery System (ATBNDDS) can increase the concentration of drugs in target cells, providing a feasible strategy for specific and efficient drug delivery. In addition, some particular types of cell membranes have been used to construct biomimetic nanocarriers due to their natural targeting ability, thus improving drug delivery efficiency. This paper reviews the research progress of ATBNDDS in improving tumor immunotherapy in recent years, and provides an outlook on the main challenges and future developments in this field.